"Dr Miller has worked for over 25 years in the bioscience...

"Dr Miller has worked for over 25 years in the bioscience industry, with extensive experience in commercial drug development. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund."

"Stephen Becker has had an extensive career as a pharmaceutical development executive in both the public and private sector organizations. He has worked extensively in the HIV and antiviral therapeutic arenas, as well at the interface of viral and cancer immunology.
Dr Becker worked for more than 6 years at the Bill & Melinda Gates foundation where he led HIV treatment, prevention and cure efforts. This included early stage development of long-acting antiretrovirals, and broadly neutralizing antibodies. He coordinated foundation-supported efforts with the NIH, biopharma, WHO and global regulatory agencies.
Dr Becker’s career in HIV began in the early 1980s while a faculty member at UCSF where he led a large HIV clinical practice, and clinical research program. His areas of research included pharmacology and pharmacogenetics, early stage drug development, and health service outcomes research."

"Dr Pond has a strong scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003-2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia."

"Professor Locarnini, is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). His current major research interests include viral hepatitis, hepatitis vaccines and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures."

As you can see It's a good Team,
All have different experience in the Industry,
And all have important contributions they make.
That makes BIT what it is and all are important parts of the puzzle....

Anyhow all those experienced people with different ways of doing things,
Really gives BIT an advantage and is a good combination.

Further Toxicology Studies of BIT225 were completed after the BIT 009 Trial in 2020.
giving BIT the ability to design clinical studies in which it can be used for up to 6 months, Where as previously they were limited to 3 Months.

BIT designed the BIT 225 010, 011, and 012 Trails after consultation with the FDA,
Feedback from potential partners, as well as advice from experienced international clinical, regulatory and industry advisors has informed every step of development activities undertaken by the Company.

Looking forward to seeing the Phase II Trial Results,
And Potential Partnership with Big Pharma Shortly....